Log in
Lost password
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Taro Pharmaceutical Industries Ltd.    TARO   IL0010827181

Delayed Quote. Delayed  - 12/01 02:51:02 pm
142.59 USD   -1.55%
11/26 PERRIGO : Mylan, Perrigo may compete for Taro
11/03 TARO PHARMACEUT : posts 2Q profit
11/03 TARO PHARMACEUT : Provides Results for September 30, 2015
News SummaryMost relevantAll newsSector news 

Taro Pharmaceutical Industries Ltd. : Taro Rejects IsZo's FY Q2 Under Reporting Allegation as Untrue and Irresponsible

11/08/2012 | 05:25pm US/Eastern

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) ("Taro" or the "Company") announced today that it delivered a letter to one of its shareholders IsZo Capital Management LP ("IsZo") in response to IsZo's letter to Taro's Special Committee of the Board of Directors dated November 5, 2012. The full text of the letter is set forth below:

Re: Taro Rejects IsZo's FY Q2 Under Reporting Allegation as Untrue and Irresponsible

Dear Mr. Sheehy,

We at Taro are very appreciative of our shareholders' communications. More recently, our ability to respond to certain inquiries has been limited in light of the pending merger between Taro and Sun Pharma and the related shareholder meeting scheduled December 6, 2012. Rather, our management team's primary focus continues to be on Taro's core business, the performance of which speaks for itself.

Without responding to your many unfounded allegations over the past few months, I feel compelled to publicly correct one of your most recent statements. In your November 5th letter and corresponding press release, you contend that Taro is "gaming its reserves." Your allegation is simply untrue and your comment is, at a minimum, irresponsible to your fellow Taro shareholders.

As a NYSE listed company, Taro takes its financial accounting and reporting obligations very seriously. Although our quarterly financial reporting is presented on an unaudited basis, the accounting methodologies used in estimating our reserves are "consistently applied" quarter to quarter, in conformity with U.S. GAAP. Over the last couple of years, at the request of our Board and Audit Committee, we have taken an extra step by having our independent auditors perform certain "agreed upon procedures" on our financial statements focusing on specific areas, including reserves, prior to issuing our quarterly releases, including that for the quarter ended September 30, 2012.

Given your broad industry knowledge, you undoubtedly appreciate that, while IMS data is useful to the industry for general U.S. market intelligence and a general understanding of long term, product trends, it is not reliable (or prepared) for consolidated financial reporting analysis as you propose.

Finally, I recognize your excitement for Taro as expressed in your letter. I believe that all Taro shareholders have benefited tremendously at what the new management team, under the leadership of Mr. Shanghvi and, subsequently, Mr. Sundaram, have accomplished since the change in control in September 2010.


/s/ Jim Kedrowski

Jim Kedrowski
Interim Chief Executive Officer


About Taro

Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company's website at www.taro.com.

Taro Pharmaceutical Industries Ltd.
William J. Coote, 914-345-9001
VP, Treasurer

© Business Wire 2012
React to this article
11/26 PERRIGO : Mylan, Perrigo may compete for Taro
11/24 TARO PHARMACEUTICAL : Sun pharma drops wind energy investment plan
11/24 TARO PHARMACEUTICAL : Drops plan to invest in suzlon's us power project
11/15 TARO PHARMACEUTICAL : A quarter miss on revenues: sun pharma
11/12 TARO PHARMACEUTICAL : "Process for the Preparation of a Stable Polymorphic Form ..
11/03 TARO PHARMACEUTICAL : posts 2Q profit
11/03 TARO PHARMACEUTICAL : Provides Results for September 30, 2015
10/27 TARO PHARMACEUTICAL : to Announce Second Quarter Results on November 3, 2015
10/01 TARO PHARMACEUTICAL : Keveyis™ dichlorphenamide 50 mg Tablets Now Availabl..
09/21 TARO PHARMACEUTICAL : Keveyis™ (dichlorphenamide) 50 mg Tablets Now Availa..
News chart
Full-screen chart
Income Statement Evolution
More Financials